When most people consider their risk for heart disease, they often focus on family history and genetics. However, a growing body of research suggests that DNA sequence alone tells only part of the story, and Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) is leveraging the science of epigenetics to fill in the gaps. Epigenetics examines how genes are switched on or off, turned up or down, without any change to the underlying DNA code itself, providing a more dynamic view of cardiovascular risk.
Cardio Diagnostics, a medical technology company, has positioned epigenetics at the center of its diagnostic platform. The company’s approach looks at an individual’s epigenetics to gain invaluable insight into the impact of lifestyle, behavior, and environment on heart disease risk. According to the CEO, epigenetics does more than pinpoint a problem; it also provides some level of solution.
Understanding the basic concept of epigenetics is key. Think of DNA as a massive instruction manual containing every gene a person could ever use. That manual does not change much over a lifetime. What does change is which pages get read, how often, and how loudly. Epigenetics is essentially the mechanism that determines gene expression, influenced by factors such as diet, exercise, stress, and environmental exposures.
This approach represents a shift from traditional genetic testing, which looks for inherited mutations. Epigenetic markers can change over time, offering a real-time snapshot of a person’s health. For patients, this means a more personalized assessment of heart disease risk and potentially earlier interventions. For the healthcare industry, it could lead to more targeted prevention strategies and treatments.
Cardio Diagnostics’ platform has the potential to impact millions of people who might otherwise be unaware of their risk. By revealing hidden dangers that standard tests might miss, the company aims to reduce the burden of cardiovascular disease, which remains a leading cause of death worldwide. The implications for public health are significant, as epigenetic testing could become a routine part of preventive care.
Investors have taken note of the company’s innovative approach. The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO. As the field of epigenetics continues to evolve, Cardio Diagnostics is positioning itself at the forefront of a new era in cardiovascular medicine.
